Mode
Text Size
Log in / Sign up
Phase 3 N=84 Randomized Quadruple-blind Treatment

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

Lumbosacral Radiculopathy

Enrolled (actual)
84
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcome: Primary: Numerical Rating Leg Pain Score — 2.54; 3.56; 3.78 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
etanercept (Drug); methylprednisolone (Drug); normal saline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Mar 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Numerical Rating Leg Pain Score
2.54; 3.56; 3.78
SECONDARY
Oswestry Disability Score
22.4; 40.26; 30.00
SECONDARY
Global Perceived Effect
23; 15; 17
SECONDARY
Medication Reduction
17; 9; 14

Summary

Lumbosacral radiculopathy is one of the leading of cause of disability in the U.S. and worldwide. Among recent reviews evaluating epidural steroid injections, some 1 but not all 2 concluded them to be effective in the long-term. In our own double-blind, placebo-controlled study evaluating epidural etanercept, the results showed significant benefit in favor of the etanercept group, but no subject was included with a duration of pain > 9 months, and the results of this study have yet to be replicated. Currently, epidural steroid injections are the most frequently performed procedures in pain clinics across the U.S. However, epidural steroids may benefit only a select group of patients. The literature on treating sciatica is notable for a lack of randomized comparative studies involving various treatments. The objective of this project is to conduct a 3-arm study to determine the efficacy of 1) transforaminal epidural corticosteroids; and 2) transforaminal epidural etanercept, in patients with lumbosacral radiculopathy.

Eligibility Criteria

Inclusion Criteria

  • Chronic low back pain of radicular origin of > 4 weeks but back pain.
  • Failure of conservative therapy to include physical and pharmacotherapy.
  • MRI evidence of a lateral or paracentral herniated disc corresponding to the patient's radicular symptoms.

Exclusion Criteria

  • Uncontrolled coagulopathy.
  • Pregnancy, which will be ruled out by a urine pregnancy test in women of childbearing age.
  • Allergy to contrast dye or amide local anesthetics.
  • Previous epidural steroid injection within last year.
  • Unstable medical or psychiatric condition (e.g. unstable angina, congestive heart failure or severe depression) that could preclude an optimal treatment response.
  • Rheumatoid arthritis or spondylarthropathy.
  • Unstable neurological condition (e.g. multiple sclerosis)
  • Systemic infection
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00733096). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search